[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"gastric-dysplasia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:gastric-dysplasia":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,52,82,109,137,168],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":32,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":51},"100616957","phase-4-esomeprazole-plus-sucralfate-for-post-esd-ulcer-healing-100616957",false,"NCT07312370","Esomeprazole Plus Sucralfate for Post-ESD Ulcer Healing","Intravenous Esomeprazole Combined With Sucralfate Suspension for Ulcer Healing and Complication Prevention After Gastric Endoscopic Submucosal Dissection: A Prospective, Randomized, Controlled Trial","Inclusion Criteria:\n\n1. Age 18-80 years, male or female\n2. Diagnosed with early gastric cancer or high-grade intraepithelial neoplasia planned for gastric ESD\n3. Lesion location: Gastric corpus, antrum, or angle (cardiac lesions may be included but will require subgroup analysis)\n4. Successful en bloc resection achieved by ESD\n5. Post-ESD artificial ulcer diameter ≥2 cm\n6. Complete coagulation of all visible vessels during ESD procedure\n7. ECOG performance status 0-1\n8. Able to comply with follow-up visits and endoscopic examinations\n9. Voluntary participation with written informed consent\n\nExclusion Criteria:\n\n1. Previous gastric surgery history\n2. Active peptic ulcer disease (confirmed by pre-ESD endoscopy) within 1 month\n3. Recent upper gastrointestinal bleeding (within 1 month, excluding tumor-related bleeding)\n4. Severe heart, liver, or kidney dysfunction (Child-Pugh class C, NYHA class III-IV, or CKD stage 4-5)\n5. Coagulation disorders (INR \\>1.5 or platelet count \\\u003C50×10⁹\u002FL)\n6. Uncontrolled diabetes (HbA1c \\>9%)\n7. Known allergy or hypersensitivity to PPIs or sucralfate\n8. Use of PPIs, H2 receptor antagonists, or mucosal protective agents within 2 weeks prior to ESD\n9. Long-term anticoagulant therapy that cannot be discontinued (e.g., warfarin, direct oral anticoagulants)\n10. Long-term NSAIDs or aspirin (\\>100mg\u002Fday) that cannot be discontinued\n11. Unsuccessful complete (en bloc) resection (piecemeal resection)\n12. Intraoperative perforation\n13. Uncontrolled active bleeding during ESD\n14. Pregnancy or lactation\n15. Women of childbearing potential not using adequate contraception\n16. Concurrent participation in another clinical trial\n17. Any condition that, in the investigator's opinion, makes the patient unsuitable for study participation","ALL","18 Years","80 Years",{"count":20,"type":21},120,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","Endoscopic submucosal dissection (ESD) is an established treatment for early gastric cancer and precancerous lesions. Post-ESD artificial ulcers may lead to complications including delayed bleeding (3-15%) and prolonged healing. Current guidelines recommend high-dose proton pump inhibitors (PPIs), but evidence for additional mucosal protective agents remains limited.\n\nThis study aims to evaluate whether combining sucralfate suspension with standard intravenous esomeprazole therapy improves ulcer healing and reduces complications after gastric ESD compared to esomeprazole alone.\n\nThis is a prospective, randomized, controlled, outcome-assessor-blinded trial. A total of 120 patients undergoing gastric ESD will be randomly assigned 1:1 to receive either:\n\n* Intervention group: Intravenous esomeprazole 40mg twice daily (3 days) followed by oral esomeprazole 40mg once daily PLUS sucralfate suspension 1g twice daily for 8 weeks\n* Control group: Intravenous esomeprazole 40mg twice daily (3 days) followed by oral esomeprazole 40mg once daily for 8 weeks The primary outcome is ulcer reduction rate at 4 weeks post-ESD, assessed by endoscopy. Secondary outcomes include complete ulcer healing rate at 8 weeks, delayed bleeding rate, symptom scores, and safety parameters.\n\nThis study will provide high-quality evidence regarding the role of sucralfate as an adjunctive therapy for post-ESD ulcer management and may inform future clinical guidelines.",[27,28,29,30,31],"Early Gastric Cancer","Gastric Dysplasia","Gastric Neoplasms","Peptic Ulcer With Haemorrhage","Gastric Ulcer",[33,34,35,36,37,38],"Endoscopic Submucosal Dissection","Gastric Cancer","Ulcer Healing","Proton Pump Inhibitor","Post-ESD Ulcer","Early Gastric Neoplasm","NOT_YET_RECRUITING","2026-03-19",{"date":42,"type":43},"2026-03-23","ACTUAL",{"date":45,"type":21},"2026-04-20",{"date":47,"type":21},"2026-12-30",{"name":49,"class":50},"LanZhou University","OTHER",1,{"id":53,"slug":54,"hasResults":11,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":4,"eligibilityCriteria":58,"healthyVolunteers":59,"sex":16,"minAge":60,"maxAge":4,"enrollmentInfo":61,"targetDuration":4,"studyType":63,"phases":4,"briefSummary":64,"conditions":65,"keywords":68,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":51},"100595477","a-cohort-study-of-mobile-capsule-gastroscopy-for-gastric-pathologies-screening-100595477","NCT07032961","A Cohort Study of Mobile Capsule Gastroscopy for Gastric Pathologies Screening","Screening for Gastric Pathologies in Elderly and High-Risk Populations Using a Mobile Capsule Gastroscopy System: a Prospective, Multicenter, Population Based Cohort Study","Inclusion Criteria:\n\n1.Provision of written informed consent; 2.Participants of the 'Gastric Pathologies Screening Programme for the Elderly and High Risk Groups in Guangzhou Municipality', the following are the criteria for inclusion in this public welfare programme:\n\n1. Elderly cohort: Permanent residents of Guangzhou aged ≥60 years who have not undergone specialized gastric disease screening in the past three years;\n2. Or high-risk cohort: Individuals aged ≥45 years who meet at least one of the following risk criteria:\n\n   1. History of Helicobacter pylori infection (positive ¹³C\u002F¹⁴C urea breath test);\n   2. Prior diagnosis of chronic atrophic gastritis, gastric ulcer, neoplastic gastric polyps, hypertrophic gastritis, or pernicious anemia;\n   3. Family history of gastric cancer (first-degree relative with a confirmed diagnosis);\n   4. Long-term high-salt diet, smoking history (≥20 pack-years), or heavy alcohol consumption (100 mL of distilled spirits\u002Fday).\n\nExclusion Criteria:\n\n1. Not considered by the investigator to be suitable for participation in this study.\n2. Meets the exclusion criteria of the Public Welfare Programme. Individuals will be excluded if they meet any of the following conditions:\n\n(1)Known allergy to medical polymer materials; (2)Psychiatric disorders that interfere with procedural cooperation; (3)Pregnancy or lactation; (4)Severe systemic comorbidities (e.g., cardiovascular, respiratory, neurological diseases) affecting examination tolerance; (5)Inflammatory bowel disease (Crohn's disease or ulcerative colitis) or gastrointestinal diverticulosis; (6)Known or suspected gastrointestinal malformations, obstructions, strictures, or fistulas; (7)Clinically significant dysphagia; (8)Acute abdominal symptoms (e.g., pain, vomiting, suspected bowel obstruction, or severe constipation); (9)History of major gastrointestinal surgery (e.g., esophagogastrostomy, gastrojejunostomy); (10)Physical debilitation precludes postural changes or concurrent severe illness; (11)Medically ineligible for abdominal procedures or refusal to undergo them; (12)Deemed unsuitable for MCG by the investigator; (13)Refusal to provide informed consent; (14)Any other condition judged by the investigator to make the individual unsuitable for study participation.",true,"45 Years",{"count":62,"type":21},10000,"OBSERVATIONAL","The goal of this is to learn about the effectiveness and feasibility of a novel AI- assisted Mobile Capsule Gastroscopy (MCG) system for detecting gastric pathologies in elderly and high-risk populations.\n\nThe main question it aims to answer is:\n\nCan MCG effectively detect gastric pathologies, including common gastric diseases, gastric cancer, and precancerous lesions, in elderly and high-risk individuals at community health centers?\n\nParticipants will:\n\nEpidemiological, diagnostic, and post-MCG follow-up data generated during participants' involvement in the gastric pathologies public screening program will be collected.",[66,28,31,34,67],"Gastritis","Gastric Mass",[69,70,71],"Capsule Endoscopy","Prospective Study","screening","RECRUITING","2025-07-03",{"date":75,"type":43},"2025-07-04",{"date":77,"type":43},"2025-06-24",{"date":79,"type":21},"2030-10-31",{"name":81,"class":50},"Nanfang Hospital, Southern Medical University",{"id":83,"slug":84,"hasResults":11,"nctId":85,"briefTitle":86,"officialTitle":87,"acronym":4,"eligibilityCriteria":88,"healthyVolunteers":59,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":89,"targetDuration":4,"studyType":22,"phases":91,"briefSummary":93,"conditions":94,"keywords":97,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":101,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":108},"100581291","capsule-gastric-endoscopy-for-gastric-disease-screening-in-simulated-home-scenarios-100581291","NCT06848400","Capsule Gastric Endoscopy for Gastric Disease Screening in Simulated Home Scenarios","A Multicenter, Prospective Study of Capsule Gastric Endoscopy for Gastric Disease Screening in Simulated Home Scenarios","Inclusion criteria\n\n1. Aged 18 years or older.\n2. Individuals meeting the following criteria:\n\n   i. Healthy volunteers; ii. Suspected presence of gastrointestinal diseases, with one or more of the following clinical symptoms: abdominal pain, nausea, vomiting, hematemesis, black or bloody stools, loss of appetite, bloating, or indigestion; iii. Follow-up of gastric lesions post-endoscopic resection.\n3. Willing to participate voluntarily in the clinical trial and provide written informed consent.\n4. Capable of communicating with researchers and complying with trial requirements.\n\nExclusion criteria\n\n1. Pregnant individuals.\n2. Individuals at high risk of gastrointestinal obstruction, including those identified as being at risk of gastrointestinal stenosis based on the Gastrointestinal Stenosis Assessment Form, those in whom gastrointestinal obstruction cannot be clinically excluded, or individuals with a history of gastrointestinal surgery, severe motor dysfunction, or pseudobulbar palsy.\n3. Individuals with swallowing dysfunction.\n4. Individuals deemed unfit for surgery or unwilling to undergo any surgical procedures.\n5. Participants who are unable to comprehend and\u002For comply with physician instructions during the examination.\n6. Individuals with other medical risks that contraindicate the use of a capsule gastric endoscopy system, or those deemed unsuitable for participation in this study at the discretion of the investigator.",{"count":90,"type":21},482,[92],"NA","The goal of this clinical trial is to evaluate the diagnostic accuracy of the AI-integrated Capsule Gastroscopy (ACG) system in simulated home-use conditions for detecting upper gastrointestinal (UGI) abnormalities. It will also compare the diagnostic accuracy and time efficiency of AI-assisted interpretation versus manual reading of ACG data. The main questions it aims to answer are:\n\nWhat is the diagnostic accuracy of the ACG system, using conventional esophagogastroduodenoscopy (EGD) as a standard of reference?\n\nDoes AI-assisted ACG reading improve diagnostic accuracy or reduce reading time compared to manual ACG video reading?\n\nResearchers will compare ACG results to conventional EGD findings (standard of reference) to determine if ACG can serve as a reliable method for UGI disease detection in home scenarios.\n\nParticipants will:\n\nUndergo an ACG examination in a simulated home environment. Complete an EGD procedure within 24 hours post-ACG ingestion.",[95,66,96,28,31,29],"Gastric Lesion","Upper Gastrointestinal Bleeding (UGIB)",[98,69,70,99,100],"upper gastrointestinal diseases","Diagnostic accuracy","Upper Gastrointestinal abnormalities",{"date":102,"type":43},"2025-07-09",{"date":104,"type":43},"2025-03-03",{"date":106,"type":21},"2026-12-31",{"name":81,"class":50},12,{"id":110,"slug":111,"hasResults":11,"nctId":112,"briefTitle":113,"officialTitle":113,"acronym":114,"eligibilityCriteria":115,"healthyVolunteers":11,"sex":16,"minAge":60,"maxAge":4,"enrollmentInfo":116,"targetDuration":4,"studyType":22,"phases":118,"briefSummary":119,"conditions":120,"keywords":123,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":129,"lastUpdatePostDateStruct":130,"startDateStruct":132,"completionDateStruct":134,"leadSponsor":135,"locationsCount":51},"100409598","surveillance-of-premalignant-stomach---individualized-endoscopic-follow-up-100409598","NCT04613570","SUrveillance of PREMalignant Stomach - Individualized Endoscopic Follow-up","SUPREME","Inclusion Criteria:\n\n* Patients scheduled for upper GI endoscopy with indication for gastric biopsies, including those with known gastric pathology (e.g. auto-immune gastritis) or premalignant conditions (e.g patients under surveillance because of atrophic gastritis);\n* Age above 45 years old\n\nExclusion Criteria:\n\n* History of previous gastrectomy;\n* History of endoscopic resection of neoplastic lesion\n* History of previous gastric dysplasia (even with no detectable lesion)\n* Hereditary syndromes that increase gastric cancer risk (familial adenomatous polyposis; Lynch syndrome)\n* Serious comorbidities (ASA 3 or more)\n* Medication with anticoagulants",{"count":117,"type":21},912,[92],"Introduction: Gastric atrophy and intestinal metaplasia are the principal precursors for gastric cancer and, therefore, are considered gastric premalignant conditions. Although current guidelines recommend surveillance of individuals with these conditions, the best method for its identification and staging (histological vs endoscopy) and the best time schedule for follow-up are still controversial. Aims: To describe for the first-time patients with premalignant conditions both clinically (familial history), histologically (OLGA\u002FOLGIM; complete\u002Fincomplete metaplasia) and endoscopically (EGGIM) using validated scales and to describe evolution of these parameters through time. To estimate prospectively the gastric cancer risk according to EGGIM stages. To define the best endoscopic surveillance follow-up for the several stages considering clinical, histological and endoscopic factors.\n\nMethods: Multicenter study involving different gastroenterology departments from several countries. Consecutive patients older than 45 years scheduled for upper endoscopy in each of these centers will be evaluated by High-Resolution- endoscopy with virtual chromoendoscopy and EGGIM will be calculated. Guided biopsies (if areas suspicious of IM) and\u002For random biopsies (if no areas suspicious of IM) in antrum and corpus will be made and OLGA\u002FOLGIM stages calculated. Patients will be evaluated in clinical consultation and database will be fulfilled. All patients will be eradicated for Helicobacter pylori infection if positive. At that occasion, all the patients with EGGIM\\>5 and\u002For OLGA III\u002FIV and\u002For OLGIM III\u002FIV will be randomized for yearly (12 to 16 months) or every three years (32-40 months) endoscopic follow-up during a period of 6 years (SUPREME I). Endoscopic observational follow-up will be scheduled for patients with EGGIM 1-4 and OLGIM I\u002FII at 3 and 6 years (SUPREME II). For individuals with no evidence of IM (EGGIM 0 and OLGIM 0, OLGA 0-II) a follow-up endoscopy 6 years after will be proposed (SUPREME III).",[121,122,28,34],"Atrophic Gastritis","Intestinal Metaplasia",[124,125,126,127,128],"atrophic gastritis","gastric cancer","intestinal metaplasia","gastric dysplasia","surveillance","2022-03-29",{"date":131,"type":43},"2022-03-31",{"date":133,"type":43},"2021-01-02",{"date":106,"type":21},{"name":136,"class":50},"Instituto Portugues de Oncologia, Francisco Gentil, Porto",{"id":138,"slug":139,"hasResults":11,"nctId":140,"briefTitle":141,"officialTitle":141,"acronym":142,"eligibilityCriteria":143,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":144,"targetDuration":4,"studyType":63,"phases":4,"briefSummary":146,"conditions":147,"keywords":149,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":158,"lastUpdatePostDateStruct":159,"startDateStruct":161,"completionDateStruct":163,"leadSponsor":165,"locationsCount":167},"100364198","screening-of-gastric-cancer-via-breath-volatile-organic-compounds-by-hybrid-sensing-approach-100364198","NCT04022109","Screening of Gastric Cancer Via Breath Volatile Organic Compounds by Hybrid Sensing Approach","VOGAS","Inclusion Criteria:\n\n* Patients with verified gastric cancer (Group 1 \\& 2)\n* Patients undergoing or having undergone upper endoscopy according to clinical indications (Group 3 \\& 5)\n* Average-risk population group aged 40-64 at inclusion without alarm symptoms (Group 4)\n* Motivation to participate in the study\n* Physical status allowing volatile marker sampling and other procedures within the protocol\n* Signed consent\n\nExclusion Criteria:\n\n* Known other active cancer\n* Ventilation problems, airway obstruction\n* Unwillingness or inability to co-operate",{"count":145,"type":21},5000,"The study is aimed to determine the potential of volatile marker testing for gastric cancer screening.\n\nThe study will be addressing the role of confounding factors, including lifestyle factors, diet, smoking as well as addressing the potential role of microbiota in the composition of exhaled volatile markers.",[34,121,28,148],"H.Pylori Infection",[150,151,152,153,154,155,156,157],"Volatile organic compounds","Breath testing","Gastric cancer","Atrophic gastritis","Precancerous lesions","Screening","Nanosensor technology","GC-MS","2021-07-19",{"date":160,"type":43},"2021-07-26",{"date":162,"type":43},"2019-11-01",{"date":164,"type":21},"2026-12",{"name":166,"class":50},"University of Latvia",5,{"id":169,"slug":170,"hasResults":11,"nctId":171,"briefTitle":172,"officialTitle":173,"acronym":4,"eligibilityCriteria":174,"healthyVolunteers":59,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":175,"targetDuration":4,"studyType":63,"phases":4,"briefSummary":177,"conditions":178,"keywords":181,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":185,"lastUpdatePostDateStruct":186,"startDateStruct":188,"completionDateStruct":190,"leadSponsor":192,"locationsCount":51},"100304969","surveillance-of-patients-with-precancerous-lesions-of-the-stomach-100304969","NCT03250091","Surveillance of Patients With Precancerous Lesions of the Stomach","Surveillance Strategies of Patients With Precancerous Conditions and Lesions in the Stomach","Inclusion Criteria:\n\nPatients undergoing upper endoscopy Motivation to participate in the study Signed consent\n\nExclusion Criteria:\n\nKnown gastric cancer Unwillingness or inability to co-operate",{"count":176,"type":21},2000,"The project will aim to identify and determine subgroups of patients with different risks of progression to gastric cancer and to assess appropriate follow-up intervals. Implementing risk stratification only high risk individuals will be offered and performed endoscopic surveillance.",[34,179,180,28],"Gastric Intestinal Metaplasia","Gastric Atrophy",[182,125,183,184,127],"gastric precancerous lesions","gastric intestinal Metaplasia","gastric atrophy","2018-08-20",{"date":187,"type":43},"2018-08-21",{"date":189,"type":43},"2017-06-19",{"date":191,"type":21},"2027-12",{"name":166,"class":50}]